Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE) (Nefigard-OLE)
An Open-Label Extension (OLE) Study to Evaluate the Efficacy and Safety of Nefecon Treatment in Patients With IgA Nephropathy Who Have Completed Study Nef-301
Sponsor: Calliditas Therapeutics AB
This PHASE3 trial investigates Primary IgA Nephropathy and is currently completed. Calliditas Therapeutics AB leads this study, which shows 11 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Mar 2025 — Sep 2025 [monthly]
Completed PHASE3
-
Feb 2025 — Mar 2025 [monthly]
Completed PHASE3
-
Nov 2024 — Feb 2025 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE3
▶ Show 6 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Aug 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Mar 2023 — Aug 2023 [monthly]
Recruiting PHASE3
-
Sep 2021 — Mar 2023 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Calliditas Therapeutics AB
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Athens, Greece , Barcelona, Spain , Brussels, Belgium , Buenos Aires, Argentina , Gyeonggi-do, South Korea , Jyväskylä, Finland , Kayseri, Turkey (Türkiye) , Leicester, United Kingdom , Lodz, Poland and 8 more locations